OBJECTIVE: To investigate the inhibitory effect of thalidomide on angiodysplasia. METHODS: Excisional intestinal specimens were collected and immunohistochemical examination was carried out. The human umbilical vein endothelial cells were cultured in vitro to exponential phase of growth, divided into six groups and synchronized for 24 hours. They were then stimulated with thalidomide (40 - 100 microg/ml) for 72 hours. MTT assay was used to assess cellular proliferation. ELISA, real-time quantitative PCR and western blot were applied to detect the expression of VEGF/HIF-1alpha of human umbilical vein endothelial cells (HUVEC). RESULTS: Immunohistochemical analysis of intestinal pathological specimens demonstrated higher expression of VEGF. ELISA showed that the expression of VEGF under hypoxia was obviously higher than that under normoxia [(1199.3 +/- 61.4) ng/L vs (864.7 +/- 41.2) ng/L, P < 0.05]. Real-time quantitative PCR and Western blot discovered that thalidomide inhibited the expression of VEGF/HIF-1alpha of HUVEC (P < 0.05). The effect of thalidomide was dose-dependent. CONCLUSIONS: Thalidomide can suppress the expression of HIF-1alpha and VEGF in HUVEC in vitro and then inhibit angiodysplasia, which may play a significant role in stopping the rebleeding in patients with recurrent gastrointestinal bleeding.
OBJECTIVE: To investigate the inhibitory effect of thalidomide on angiodysplasia. METHODS: Excisional intestinal specimens were collected and immunohistochemical examination was carried out. The human umbilical vein endothelial cells were cultured in vitro to exponential phase of growth, divided into six groups and synchronized for 24 hours. They were then stimulated with thalidomide (40 - 100 microg/ml) for 72 hours. MTT assay was used to assess cellular proliferation. ELISA, real-time quantitative PCR and western blot were applied to detect the expression of VEGF/HIF-1alpha of human umbilical vein endothelial cells (HUVEC). RESULTS: Immunohistochemical analysis of intestinal pathological specimens demonstrated higher expression of VEGF. ELISA showed that the expression of VEGF under hypoxia was obviously higher than that under normoxia [(1199.3 +/- 61.4) ng/L vs (864.7 +/- 41.2) ng/L, P < 0.05]. Real-time quantitative PCR and Western blot discovered that thalidomide inhibited the expression of VEGF/HIF-1alpha of HUVEC (P < 0.05). The effect of thalidomide was dose-dependent. CONCLUSIONS:Thalidomide can suppress the expression of HIF-1alpha and VEGF in HUVEC in vitro and then inhibit angiodysplasia, which may play a significant role in stopping the rebleeding in patients with recurrent gastrointestinal bleeding.